Loading…
← CockpitCompetitor Analysis › 197A.T Tauns Laboratories, Inc.Open in the cockpit ↗

Tauns Laboratories, Inc.197A.TCompetitor analysis, valuation and peers

Japan · JPY·Health Care›Medical Specialties
Momentum neutral 53
Mkt cap
$327M
US dollars, full cap
Free float
31%
of shares outstanding
$/day
$1.16M
20-day average traded
Fwd P/E
16.7×
forward earnings
ROIC−WACC
+4.1 pp
WACC 5.2%
Hurdle
n/a
no reverse DCF
Next earnings
86 days
12 Feb 2027
Close · JPY¥487
1D-0.6%
1W+0.6%
1M-3.8%
3M0.0%
6M-3.2%
YTD-4.3%
1Y-13.3%
ATR %2.6%
52w lowhigh15.6% off high

What Tauns Laboratories does

Employees: 350

Tauns Laboratories at a glance

Size Tauns Laboratories (197A.T) is a Japan Health Care company (Medical Specialties) with a market value of $327M, the 1303rd largest of 1,370 Japan companies the cockpit tracks. Shares closed at ¥487 on 18 Nov 2026.

Performance Over six months the shares fell 3.2%, against -20.4% for the median peer and -1.4% for the Japan market (cap-weighted) — 7th highest of 21 in its peer set.

Growth Revenue grew 7.2% over the last twelve months (peer median +2.2%); the operating margin is 29.3% (peer median 7.9%).

Valuation It trades at 16.7× forward earnings against a peer median of 17.8× (6th cheapest of 13).

Capital Return on invested capital runs 4.1 points above its cost of capital (5.2% WACC).

Next results Next results expected around 12 Feb 2027 (exchange calendar; dates can move).

Relative performance

809010021 May 202621 Aug 202618 Nov 2026197A.T 97Peer median 80
Six months, rebased to 100: Tauns Laboratories against the median of its 20 peers (local-currency closes).

Tauns Laboratories financials

Reported figures in JPY; fiscal year ends 2026-06-30. TTM = trailing twelve months.
TTMFY2026FY2025FY2024FY2023
Revenue¥15.6B¥14.4B¥18.6B¥18.4B¥15.7B
Revenue growth—-23%+1%+18%—
Gross profit¥9.46B¥8.29B¥12.3B¥12.1B¥8.79B
EBITDA¥5.92B¥5.33B¥8.98B¥8.71B¥5.61B
Net income¥5.71B¥5.50B¥6.32B¥5.77B¥3.03B
Free cash flown/a-¥6.61B¥2.14B¥6.18B-¥4.25B
Capital expendituren/a¥4.02B¥5.12B¥3.96B¥1.17B
Total debt¥19.9B¥21.3B¥14.4B¥9.54B¥6.47B

Quarterly statements and history in the cockpit →

Tauns Laboratories competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-50%0%+50%-10%0%6884683007533009423015023777405889688273CLTNYDESEMBCVBSN300653688576SMTI99966883381609SBSCV688314197A.T6-month return →1-month return →
Up and to the right = strong over both horizons. Tauns Laboratories is the large dot.

Fundamentals: revenue growth against valuation

-20%0%+20%0×250×500×750×3007533777405889688273CLTNEMBC300653688576SMTI9996197A.TRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Tauns Laboratories is the large dot.

Tauns Laboratories competitors and peer comparison

How Tauns Laboratories compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Tauns Laboratories against its 20 peers (data as of 18 Nov 2026)
Measure197A.TPeer medianRank in peer set
1-month return-3.8%-10.9%8th highest of 21
6-month return-3.2%-20.4%7th highest of 21
Distance from 52-week high-15.6%-48.0%3rd highest of 21
Revenue growth (TTM)+7.2%+2.2%10th highest of 21
Operating margin29.3%7.9%4th highest of 21
Forward P/E16.7×17.8×6th cheapest of 13
ROIC minus cost of capital+4.1 pp+1.9 pp10th highest of 19
EV / EBITDA11.5×7.8×4th most expensive of 10
Net debt / EBITDA2.7×1.3×2nd most indebted of 10

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Tauns Laboratories 197A.TJapan$327M-3%+7%29%16.7×n/an/a
Chemclin Diagnostics 688468.SSChina$327M-24%-10%4%n/a15.8%-4.5%
Jiangsu Apon Medical Technology 300753.SZChina$326M-34%-15%-10%862.0×20.0%-5.1%
Shenzhen Bioeasy Biotechnology 300942.SZChina$326M-27%+12%-2%n/an/an/a
Jiangsu Huayang Intelligent Equipment 301502.SZChina$336M-36%-5%2%n/a34.3%+0.4%
BioNote 377740.KSSouth Korea$337M-14%+12%18%14.4×-15.0%-28.5%
Japan Eyewear 5889.TJapan$318M-5%+15%32%10.7×-9.4%+20.2%
Nanjing Medlander Medical Technology 688273.SSChina$337M-47%-12%8%17.5×35.3%+5.2%
COLTENE CLTN.SWSwitzerland$339M-7%-2%8%25.2×-0.3%-0.7%
YD Bio YDESUnited States$344M+7%+17%-883%n/an/an/a
Embecta EMBCUnited States$345M+99%-8%26%3.8×-19.9%-0.1%
IVF HARTMANN VBSN.SWSwitzerland$352M-2%+7%14%n/a-12.7%-1.3%
Yantai Zhenghai Bio-Tech 300653.SZChina$354M-23%-8%17%36.0×18.4%+4.4%
Chongqing Xishan Science and Technology 688576.SSChina$301M-40%-23%-29%12.8×n/an/a
Sanara MedTech SMTIUnited States$301M+42%+10%11%59.0×19.5%+45.9%
Peijia Medical 9996.HKHong Kong$296M-34%+21%-13%292.4×n/an/a
Beijing Succeeder Technology 688338.SSChina$362M-18%-4%31%16.4×5.7%+3.4%
Star Sports Medicine 1609.HKHong Kong$364M-73%+23%37%n/a-13.1%+36.8%
Stratec SBS.DEGermany$365M+63%-6%4%18.2×19.1%+0.1%
CapsoVision CVUnited States$366M+5%+15%-213%n/an/an/a
Kontour (Xi'an) Medical Technology 688314.SSChina$291M-46%+8%24%n/a3.1%+16.4%

Questions

Which companies are Tauns Laboratories's closest peers?
The cockpit's peer set: Chemclin Diagnostics (688468.SS), Jiangsu Apon Medical Technology (300753.SZ), Shenzhen Bioeasy Biotechnology (300942.SZ), Jiangsu Huayang Intelligent Equipment (301502.SZ), BioNote (377740.KS), Japan Eyewear (5889.T), Nanjing Medlander Medical Technology (688273.SS), COLTENE (CLTN.SW).
Is Tauns Laboratories expensive compared with its peers?
On forward p/e it trades at 16.7× against a peer median of 17.8×, 6th cheapest of 13 in its peer set.
How has Tauns Laboratories stock performed?
Over six months to 18 Nov 2026 the shares returned -3.2% against -20.4% for the median peer; over one year -13.3%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.